NVOB Novo-N.Dkk1'b'

 
TIDMNVOB 
 
Novo Nordisk A/S - Share repurchase programme 
 
On 2 February 2010 Novo Nordisk initiated its share repurchase programme in 
accordance with the provisions of the European Commission's regulation no 
2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. 
 
Under the programme Novo Nordisk will repurchase B shares for an amount up to 
DKK 2.0 billion in the period from 2 February 2010 to 26 April 2010. 
 
 
Since the announcement as of 2 February 2010, the following transactions have 
been made under the programme: 
 
                   Number of    Average     Transaction value, 
                    shares   purchase price         DKK 
 
 2 February 2010     165,000       368.1829         60,750,179 
 
 3 February 2010      90,000       374.2699         33,684,291 
 
 4 February 2010      90,000       378.6587         34,079,283 
 
 5 February 2010      90,000       375.1000         33,759,000 
 
 Accumulated under 
 the programme       435,000                       162,272,753 
 
 
Transactions related to Novo Nordisk's incentive programmes have resulted in a 
net sale by Novo Nordisk of 1,381,775 B shares in the period from 2 February 
2010 to 5 February 2010. The shares in these transactions were not part of the 
Safe Harbour repurchase programme. 
 
With the transactions stated above, Novo Nordisk owns a total of 31,191,170 
treasury shares, corresponding to 5.0% of the share capital. The total amount of 
shares in the company is 620,000,000 including treasury shares. 
 
 
Novo Nordisk is a healthcare company and a world leader in diabetes care. In 
addition, Novo Nordisk has a leading position within areas such as haemostasis 
management, growth hormone therapy and hormone replacement therapy. Novo Nordisk 
manufactures and markets pharmaceutical products and services that make a 
significant difference to patients, the medical profession and society. With 
headquarters in Denmark, Novo Nordisk employs more than 29,300 employees in 76 
countries, and markets its products in 179 countries. Novo Nordisk's B shares 
are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed 
on the New York Stock Exchange under the symbol 'NVO'. For more information, 
visit novonordisk.com. 
 
 
Further information: 
 
 
 Media:                                  Investors: 
 
 
 Elin K Hansen                           Klaus Bülow Davidsen 
 
 Tel: (+45) 4442 3450                    Tel: (+45) 4442 3176 
 
 ekh@novonordisk.com                     klda@novonordisk.com 
 <mailto:ekh@novonordisk.com>            <mailto:klda@novonordisk.com> 
 
 
                                         Kasper Roseeuw Poulsen 
 
                                         Tel: (+45) 4442 4471 
 
                                         krop@novonordisk.com 
                                         <mailto:krop@novonordisk.com> 
 
 
 In North America:                       In North America: 
 
 Sean Clements                           Hans Rommer 
 
 Tel: (+1) 609 514 8316                  Tel: (+1) 609 919 7937 
 
 secl@novonordisk.com                    hrmm@novonordisk.com 
 <mailto:secl@novonordisk.com>           <mailto:hrmm@novonordisk.com> 
 
 
Company Announcement no 7 / 2010 
 
 
 
 
[HUG#1381804] 
 
 
 
 
 
    Company Announcement no 7 2010: http://hugin.info/2013/R/1381804/340902.pdf 
 

Novo-N.Dkk1'b' (LSE:NVOB)
Historical Stock Chart
Von Apr 2024 bis Mai 2024

Novo-N.Dkk1'b' (LSE:NVOB)
Historical Stock Chart
Von Mai 2023 bis Mai 2024